Roche’s antiviral hits flu targets in PhIII trial
Roche says its investigational flu drug baloxavir marboxil, in-licensed from Japan’s Shionogi, has met key goals in a late-stage trial.
Read More
Tag: CAPSTONE-2
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
